Tumori Journal Abstract Book - October 2020 - 50

50	
in combination with immune checkpoint inhibitors in the
frontline setting. Real-life clinical data of CABO for HCC
are lacking, as its approval by most national drugs agencies is still pending. In Italy, the manufacturing company
can currently provide CABO for HCC patients with no
therapeutic alternatives, after individual request by physicians, in the legal context of named patient use.
Patients and methods: We evaluated clinical data and
outcome of HCC patients who received CABO in the mentioned context in different Italian centres.
Results: Fifty-two patients from 7 centres received CABO
according to EMA recommendations (median follow-up: 7.1
months). All patients had preserved liver function (ChildPugh A), mostly with an advanced HCC (80.8%) in a thirdline setting (88.0%). Prevalence of performance status>0,
macrovascular invasion, extrahepatic spread, and alfa-fetoprotein>400 ng/ml was 42.3, 34.6, 75.0, and 38.5%, respectively. Median overall survival was 12.9 months (95% CI
8.7-17.1). Median progression-free survival was 5.1 months
(95% CI 2.7-7.5). Disease control rate was 59.2% with no
objective responses. Most common treatment-related adverse
events (AEs) were: fatigue (75.0%), diarrhoea (59.6%), anorexia (44.2%), HFSR (42.3%), weight loss (28.8%), hypertension (26.9%), abdominal pain (23.1%), dysphonia
(17.3%), ALT increase (17.3%), hypothyroidism (13.5%),
nausea (13.5%), mucositis (13.5%),thrombocytopenia
(11.5%), skin rash (11.5%). Most common treatment-related
Grade 3-4 AEs were: fatigue (9.6%), HFSR (7.7%), hypertension (5.8%), ALT increase (5.8%). No treatment-related
deaths were observed. Serious AEs included: liver failure
(n=1), pulmonary embolism (n=1), cerebral haemorrhage
(n=1). Most patients (78.8%) required temporary drug stops.
Permanent reduction to 40 or 20 mg/day was needed in
46.2% and 17.3% of patients, respectively. Rate of permanent discontinuation for intolerance was 17.3%.
Conclusions. In a real-life Western scenario (mostly in a
third-line setting) CABO maintained efficacy data comparable with those reported in its registrative trial. Also, the
safety profile was acceptable with no new signals.

Tumori Journal 106(2S)
better stratify patient risk in the palliative setting. Preclinical studies demonstrated Caveolin-1 (Cav-1) role as
enhancer of tumour invasiveness, promoting epithelial-tomesenchymal transition. We aim to investigate the impact
of Cav-1 on outcome of metastatic PC patients (pts) treated
with first-line chemotherapy.
Material and methods: Twenty-five tissue samples, both
liver metastasis and primary PC, were collected retrospectively in our Institution. Tissue Caveolin-1 (Cav-1-T) evaluation was performed by immunohistochemistry (IHC). In
the prospective cohort Cav-1 expression was assessed in
circulating exosomes. Data concerning response to treatment, overall survival (OS) and progression free survival
(PFS) were available for 16 pts and 8 pts of the retrospective and prospective cohorts respectively, and were calculated by Kaplan-Meier method. Survival differences were
assessed by log-rank test. Association between categorical
variables was performed by Chi-square test. Level of statistical significance alpha was set at 0.05.
Results: Median OS (mOS) and median PFS (mPSF) of the
retrospective cohort were 11 and 4.5 months, whereas the
mOS and mPFS of the prospective cohort were 11.04 and
6.16 months. Negative (grade 0-1) IHC Cav-1-T staining was
observed in 12 primary tumors samples, intermediate (grade
2) in 5 metastases and 4 primary samples, high (grade 3) in 4
metastases. Differences in Cav-1-T staining between primary
tumors and liver metastases were statistically significant
(p=0.0001). Cav-1-T positive pts (9/16) had worse mOS
compared to Cav-1-T negative ones (9.93 vs 31.92 months,
p=0.09), but a statistically significant difference in mPFS was
observed (3.68 vs 13.55 months; p=0.02). Positive Cav-1-T
expression was also associated with greater risk of progression at the first radiological assessment (p=0.02). In the prospective cohort pts with higher exosomal Cav-1 concentration
at baseline showed worse mOS (5.8 vs 16.45 months,
p=0.045) and lower mPFS (3.47 vs 8 months; p=0.21).
Conclusions: Our study suggests Cav-1 as a poor prognostic biomarker for advanced PC pts, related to liver
metastasis and higher tumor aggressiveness. Further studies are awaited to better clarify its role in promoting cancer
progression in PC.

C10
Metastatic pancreatic cancer:
the prognostic role of Caveolin-1

C11

Pecci F.1, Bittoni A.1, Mentrasti G.1, Pellei C.1, Zizzi A.2, Mandolesi
A.2, Piva F.3, Murrone A.1, Cantini L.1, Crocetti S.1, Meletani
T.1, Baleani M.G.1, Copparoni C.1, Lupi A.1, Lenci E.1, Giglio E.1,
Giampieri R.1, Berardi R.1

A SYSTEMATIC REVIEW AND METAANALYSIS ON THERAPEUTIC
STRATEGIES IN RESECTED/RESECTABLE
PANCREATIC CANCER PATIENTS

1
Clinica Oncologica, Università Politecnica delle Marche, AOU Ospedali
Riuniti, Ancona; 2Anatomia Patologica, Università Politecnica delle Marche,
AOU Ospedali Riuniti, Ancona; 3 Università Politecnica delle Marche, Ancona

Background: Pancreatic cancer (PC) detains a dismal
prognosis, showing a 5-year survival rate of 5%. The
detection of potentially prognostic biomarkers is needed to

Ciliberto D.1, Staropoli N.1, Ierardi A.1, Cuomo O.1, Calandruccio
N.D.1, Caridà G.1, Barbieri V.1, Tassone P.2, Tagliaferri P.2
1
Medical Oncology Unit Department of Experimental and Clinical Medicine,
Magna Græcia University and Cancer Center, Campus Salvatore Venuta,
Catanzaro, Italy;, Catanzaro; 2Translational Medical Oncology Unit
Department of Experimental and Clinical Medicine, Magna Græcia University
and Cancer Center, Campus Salvatore Venuta, Catanzaro, Italy
Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020
